Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Jorge J. Castillo, Andrew R. Branagan, David Sermer, Catherine A. Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy White, Alexa Canning, Maria L. Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nicholas Tsakmaklis, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon, Shayna Sarosiek

Blood (2024) 143 (7): 582–591.

https://doi.org/10.1182/blood.2023022420

Published: 2024

Includes: Supplemental data

Journal Articles

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Maria Luisa Guerrera, Zachary R Hunter, Kris Richardson, Nickolas Tsakmaklis, Amanda Kofides, Shirong Liu, Christopher J Patterson, Eugenio Morelli, Jorge J. Castillo, Shayna R Sarosiek, Catherine A. Flynn, Kirsten Meid, Andrew R. Branagan, Ruben D. Carrasco, Kenneth C. Anderson, Nikhil C Munshi, Steven P Treon, Xia Liu

Blood (2023) 142 (Supplement 1): 3303.

https://doi.org/10.1182/blood-2023-190880

Published: 2023

Journal Articles

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Narsis Attar, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Matthew J. Frigault, Noopur Raje

Blood (2023) 142 (Supplement 1): 6924.

https://doi.org/10.1182/blood-2023-182212

Published: 2023

Journal Articles

Prospective Study of Acalabrutinib with Rituximab in Patients with Symptomatic Anti-MAG Mediated IgM Peripheral Neuropathy

Shayna R Sarosiek, Andrew R. Branagan, Christopher Doughty, Catherine A. Flynn, Megan Little, Katherine Stockman, Timothy P. White, Kirsten Meid, Steven P Treon, Jorge J. Castillo

Blood (2023) 142 (Supplement 1): 213.

https://doi.org/10.1182/blood-2023-185113

Published: 2023

Journal Articles

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob Laubach, Jacalyn Rosenblatt, Nora Horick, Paul G. Richardson, Noopur Raje, Diana Cirstea

Blood (2023) 142 (Supplement 1): 4671.

https://doi.org/10.1182/blood-2023-181019

Published: 2023

Journal Articles

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Nickolas Tsakmaklis, Zachary R Hunter, Xia Liu, Amanda Kofides, Shirong Liu, Alexa G Canning, Kris Richardson, Maria Luisa Guerrera, Christopher J Patterson, Kirsten Meid, Timothy P. White, Megan Little, Katherine Stockman, Joshua Gustine, Catherine A. Flynn, Andrew R. Branagan, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon

Blood (2023) 142 (Supplement 1): 211.

https://doi.org/10.1182/blood-2023-190520

Published: 2023

Journal Articles

Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Catherine A. Flynn, Megan Little, Katherine Stockman, Timothy P. White, Alexandra N. Eurell, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Kirsten Meid, Christopher J Patterson, Zachary R Hunter, Steven P Treon

Blood (2023) 142 (Supplement 1): 1661.

https://doi.org/10.1182/blood-2023-174375

Published: 2023

Journal Articles

Skin Punch Biopsy Findings in Patients with IgM MGUS and Waldenström Macroglobulinemia Presenting with Peripheral Neuropathy

Shayna Sarosiek, Helmut G Rennke, Catherine A. Flynn, Christopher T Doughty, Andrew R. Branagan, Steven P Treon, Jorge J. Castillo

Blood (2022) 140 (Supplement 1): 6507–6508.

https://doi.org/10.1182/blood-2022-169977

Published: 2022

Journal Articles

Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression

Blood (2022) 140 (Supplement 1): 1740–1741.

https://doi.org/10.1182/blood-2022-170412

Published: 2022

Journal Articles

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 1549–1550.

https://doi.org/10.1182/blood-2022-169863

Published: 2022

Journal Articles

Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 3541–3542.

https://doi.org/10.1182/blood-2022-170254

Published: 2022

Journal Articles

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna Sarosiek, Andrew R. Branagan, David J. Sermer, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy P White, Kirsten Meid, Alexa Canning, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P Treon

Blood (2022) 140 (Supplement 1): 564–565.

https://doi.org/10.1182/blood-2022-155610

Published: 2022

Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C Mo, Omar Nadeem, Andrew J. Yee, Andrew R. Branagan, Jacob Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Jacalyn Rosenblatt, Nora K. Horick, Paul G. Richardson, Noopur Raje

Blood (2022) 140 (Supplement 1): 7282–7283.

https://doi.org/10.1182/blood-2022-156328

Published: 2022

Journal Articles

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Blood (2022) 140 (Supplement 1): 10094–10096.

https://doi.org/10.1182/blood-2022-167899

Published: 2022

Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob P. Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Kerry Spillane, Brenton LaStofka, Jacalyn Rosenblatt, Noopur S. Raje, Paul G. Richardson

Blood (2021) 138 (Supplement 1): 5043.

https://doi.org/10.1182/blood-2021-146284

Published: 2021

Journal Articles

Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma

E. Bridget Kim, Elizabeth O'Donnell, Andrew R. Branagan, Jill N. Burke, Cynthia C. Harrington, Emerentia Agyemang, Noopur S. Raje, Andrew J. Yee

Blood (2021) 138 (Supplement 1): 5018.

https://doi.org/10.1182/blood-2021-153751

Published: 2021

Journal Articles

Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma

Jessica S. Little, Parth Shah, Adam S. Sperling, Andrew R. Branagan, Omar Nadeem, Andrew J. Yee, Noopur S. Raje, Nikhil C. Munshi, Sarah Hammond

Blood (2021) 138 (Supplement 1): 3839.

https://doi.org/10.1182/blood-2021-153942

Published: 2021

Journal Articles

Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

Elizabeth K. O'Donnell, Yael Shapiro, Omar Nadeem, Andrew J. Yee, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia Agyemang, Cynthia C. Harrington, Jill N. Burke, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri

Blood (2021) 138 (Supplement 1): 4082.

https://doi.org/10.1182/blood-2021-146342

Published: 2021

Journal Articles

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Blood (2021) 138 (Supplement 1): 3801.

https://doi.org/10.1182/blood-2021-154089

Published: 2021

Journal Articles

Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma

Elizabeth K. O'Donnell, Yael Shapiro, Omar Nadeem, Andrew J. Yee, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia Agyemang, Jill N. Burke, Cynthia C. Harrington, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri

Blood (2021) 138 (Supplement 1): 3044.

https://doi.org/10.1182/blood-2021-146290

Published: 2021

NARROW

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Prospective Study of Acalabrutinib with Rituximab in Patients with Symptomatic Anti-MAG Mediated IgM Peripheral Neuropathy

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Skin Punch Biopsy Findings in Patients with IgM MGUS and Waldenström Macroglobulinemia Presenting with Peripheral Neuropathy

Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma

Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma

Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only